Table 1.
Subject population. Subject demographics, clinical characterization, and lesion volume for healthy volunteers (HV) and patients (P). IDH, isocitrate dehydrogenase; GBM, glioblastoma; NA, not applicable; Sx, surgery; CCNU, lomustine; RT, radiation therapy; TMZ, temozolomide.
| Subject ID | Diagnosis | Prior disease status | Age (yr), Sex | No. serial scans (total timespan) | Prior treatment | Treatment at the time of imaging | T2L, CEL volume (cm3) |
|---|---|---|---|---|---|---|---|
| HV1 | NA | NA | 41 M | 1 | NA | NA | NA |
| HV2 | NA | NA | 59 M | 2 (30 min) | NA | NA | NA |
| HV3 | NA | NA | 40F | 3 (174 dy) | NA | NA | NA |
| P1 | IDH mutant anaplastic oligodendroglioma | Recurrent | 52 M | 3 (578 dy) | 2 Sx, RT/TMZ, TMZ, CCNU | Sx, RT | 8–16, <1 |
| P2 | IDH mutant GBM | Recurrent | 30F | 9 (512 dy) | 3 Sx | RT/TMZ, bevacizumab, pembrolizumab, CCNU, carboplatin | 17–124, <1–6 |
| P3 | IDH mutant GBM | Recurrent | 42 M | 3 (301 dy) | 2 Sx, RT/TMZ, TMZ, bevacizumab | Bevacizumab | 27–47, 6–12 |
| P4 | IDH mutant oligodendroglioma | Non-Recurrent | 49F | 2 (224 dy) | Sx | None | 44–87, 0 |
| P5 | IDH wildtype GBM | Recurrent | 55F | 4 (225 dy) | Sx, RT/TMZ, veliparib/placebo | Sx, RT pembrolizumab | 26–175, 2–12 |